002020 京新药业
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,149,92111.02%3,998,8353,779,8463,466,5503,258,075
减:营业总成本1,735,6338.37%3,367,0363,084,8492,841,5132,739,989
    其中:营业成本1,041,1228.63%1,976,4881,766,1491,543,6591,273,328
               财务费用(36,658)12.24%(53,828)(72,321)(37,581)(2,612)
               资产减值损失1,409-55.01%(21,145)(20,898)(10,271)(2,233)
公允价值变动收益853-14.83%36,77123,9527,233131,493
投资收益(132)-102.93%6,44119,41648,15859,662
    其中:对联营企业和合营企业的投资收益----(6,042)(4,165)(4,252)(6,235)
营业利润476,17130.59%714,059756,616698,053765,386
利润总额480,12231.55%708,041750,316699,536758,979
减:所得税费用74,25259.55%84,62382,49381,572105,652
净利润405,87027.45%623,418667,823617,963653,327
减:非控股权益3,74848.54%4,5205,5695,422257
股东净利润402,12327.28%618,898662,254612,542653,070

市场价值指针
每股收益 (元) *0.47027.03%0.7200.7700.7500.820
每股派息 (元) *----0.3000.3000.3000.350
每股净资产 (元) *6.5708.69%6.4025.9775.3215.553
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容